Orthovita Inc.

Paul G. Thomas. Mr. Thomas has served as Director, President and Chief Executive Officer of LifeCell since October 1998. Mr. Thomas was elected Chairman of the Board in June 1999. Prior to joining LifeCell, Mr. Thomas was President of the Pharmaceutical Products Division of Ohmeda Inc., a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas was responsible for the overall operations of Ohmeda's Pharmaceutical Division, which had worldwide sales of approximately $200 million in 1997. Mr. Thomas received his M.B.A. degree with an emphasis in Marketing and Finance from Columbia University Graduate School of Business and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael's College in Vermont, where he graduated Cum Laude. Mr. Thomas serves as a director of Innovative Spinal Technologies, Inc., a privately held medical technology company focused on developing minimally invasive treatments for spinal disorders and Orthovita, Inc., (NASDAQ: VITA) a company specializing in biomaterial products for the restoration of the human skeleton.

Mr. Penn is a Managing Member of the general partner, a Member of the investment committee, and a Managing Director of the management company of Penn Venture Partners L.P. Mr. Penn is also a Senior Partner of Meridian Capital Partners, a Radnor, PA based private equity firm. He has over 25 years? experience in starting, managing, and financing high growth companies in the Mid-Atlantic region and nationally. Before joining Meridian, he was a Partner at Boston Millennia Partners, a $700 million venture firm focusing on technology investing with an emphasis in life science and healthcare. From 1994 to 1998, Mr. Penn was President and CEO of Tektagen, Inc., a leading contract services firm serving the biotechnology and pharmaceutical industries, which was successfully sold to Charles River Laboratories, Inc. Prior to Tektagen, he was President of Independence Ventures, Inc., a firm that specialized in starting and building high-potential, technology-based companies. Earlier in his career he held several positions in industry and venture capital. Mr. Penn is the founder of the Entrepreneurs? Forum of Greater Philadelphia. He also served as President of the Pennsylvania Biotechnology Association and was Co-Chair of Pennsylvania?s Technology 21 Biotechnology Network among other community activities. Mr. Penn holds BS degrees from MIT in metallurgy and materials science and in industrial management, an MBA from Stanford, and a JD from the University of Pennsylvania.

David F. Fitzgerald became a director of the Company in April 2003. Mr. Fitzgerald spent twenty-five years in management positions at Pfizer, Inc., serving as President and Chief Executive Officer of its Howmedica division during his last fifteen years with the company, prior to retiring in 1996. Mr. Fitzgerald also serves on the boards of LifeCell Corp. and Orthovita Inc. He holds a B.S. from American International College and M.B.A. from New York University.

Joseph is currently a venture partner and a fund manager of Trillium Lakefront Partners III, an expansion stage technology venture capital fund. Joseph formerly served as senior vice president and director of Corporate Strategy and Development for SmithKline Beecham, currently Glaxo SmithKline, a multi-billion dollar global research-based pharmaceutical company. In that role, he analyzed, planned and executed strategic transactions for the company, including acquisitions, divestitures and joint ventures. During his tenure there, he completed several transactions totaling in excess of $2 billion, including the sale of SB Clinical Laboratories to Quest Diagnostics, Inc. and the sale of Diversified Pharmaceutical Systems to Express Scripts, Inc. Prior to his position with SmithKline Beecham, Joseph served as managing director of business development for Eastman Kodak Company, a global manufacturer and marketer of traditional and digital imaging products and services. In this position, he planned and managed more than 45 strategic transactions, including acquisitions, divestitures, joint ventures and licensing transactions, totaling in excess of $10 billion. These transactions included the sale of Kodak's Clinical Diagnostics Division to Johnson & Johnson, a joint venture with Matsushita Electric, Inc. and the sale of Verbatim Corporation to Mitsubishi Kasai. Joseph has also served in senior management positions with companies manufacturing and marketing electronics and medical devices.

Mr. Koblish has served as President and Chief Executive Officer of Orthovita since April 2002, after serving as Senior Vice President of Commercial Operations since June 2001. From January 1999 to June 2001, Mr. Koblish managed Orthovita’s Worldwide Marketing division. Prior to 1999, Mr. Koblish served as Director of Marketing and Product Development, Reconstructive Specialty Group of Howmedica, Inc., a subsidiary of Pfizer, Inc. Mr. Koblish serves on the board of Pennsylvania Bio, a trade association representing Pennsylvania’s biosciences community. He earned a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute and a Master of Science degree in Engineering, Mechanical Engineering and Applied Mechanics from the University of Pennsylvania.

Mr. Pavucek has been Orthovita’s Chief Financial Officer since February 2007, after serving as Vice President, Finance and Controller since September 2006. Before joining Orthovita, Mr. Pavucek served as Vice President, Finance and Operations, of PDI, Inc., a publicly traded biopharmaceutical commercialization partner, from 2002 to September 2006. Mr. Pavucek also served as Executive Director, Controller of PDI, Inc. from 2001 to 2002. He holds Bachelor and Master Degrees in Business Administration from Temple University, and is a Fellow Alumnus of the Wharton School of Business at the University of Pennsylvania.

Dr. Persenaire has served as Orthovita’s Chief Medical Officer since April 1999. Prior to joining Orthovita, Dr. Persenaire was Vice President of Clinical Affairs at AcroMed Corporation, a DePuy-Johnson & Johnson company. Fluent in four languages, Dr. Persenaire received his medical degree from Groningen University in The Netherlands in 1982 and served his residencies in internal medicine and surgery at St. Geertruiden and Naval Hospitals in The Netherlands.

Mr. Smith has been Orthovita’s Senior Vice President of Sales and Marketing since July 2007 after serving as Senior Vice President of U.S. Sales from March 2006 to June 2007 and Vice President, Sales from February 2004 to February 2006. From 1999 to 2004, he was a group director at Medtronic Neurologic Technologies, a division of Medtronic, Inc. From 1992 to 1999, Mr. Smith founded and was President of ThoroughMed Inc., a spine, neurosurgery and biomaterials distributor agency based in New York. ThoroughMed was acquired by Medtronic in 1999 and incorporated into Medtronic’s Neurologic Technologies sales division.

Mr. McIlhenny has been Orthovita’s Senior Vice President, Operations, since December 2002. From January 1996 to December 2002, Mr. McIlhenny served Orthovita in several capacities, namely Vice President of Quality Assurance and Regulatory Affairs, Vice President of Quality Systems and Operations Support, and Director of Manufacturing and Quality Control. From 1991 to 1995, Mr. McIlhenny was Director of Operations and Engineering at Surgical Laser Technologies, Inc., a company that developed, manufactured and marketed regulatory approved medical lasers and disposable fiber optic laser delivery systems. He received a Bachelor of Science degree in Civil Engineering from The Pennsylvania State University, a Bachelor of Science degree in Mechanical Engineering from Drexel University and a Master of Business Administration degree from Old Dominion University.

Mr. Low has served as Orthovita’s Senior Vice President, European Operations, since April 2006, after serving as Vice President, European Operations since May 2002. Mr. Low served as Director of European Operations from December 2001 to May 2002, and as Director of Marketing for Orthovita’s European operations from September 2001 to December 2001. Prior to joining the Company, he held senior marketing positions at both Howmedica and DePuy, a Johnson & Johnson company, where he was responsible for the International Knee Business Unit. He graduated in 1981 with a combined Bachelor of Arts degree in Economics and Marketing from the University of Strathclyde, Glasgow.

Mary E. Paetzold was Vice President, Chief Financial Officer, Secretary, Treasurer and a member of the Board of Directors of Ecogen, Inc., where she worked from 1994 to 2000. Prior thereto, Ms. Paetzold was an audit partner and SEC reviewing partner for KPMG LLP, in Short Hills, New Jersey, where she worked for 21 years. She also served as chairperson of the Advisory Council of the School of Business at Montclair State University, where she earned an undergraduate degree in mathematics. Ms. Paetzold is a certified public accountant.

Mr. Barry joined Essex from Novartis Pharma AG where he most recently served as the Global Head of Pharma M&A and Collaborations. In this role, he was responsible for global acquisitions, equity investments and corporate partnerships across all therapeutic areas. He joined Novartis in 2002 and held positions in the Business Development & Licensing and Mergers & Acquisitions groups. Prior to joining Novartis, Mr. Barry was a Director for Century Capital Associates LLC, a boutique healthcare investment bank and consulting firm. There he focused on mergers & acquisitions, strategic partnering and financing transactions. Previously, Mr. Barry held positions at KPMG LLP in their healthcare corporate finance group and assurance services group. Mr. Barry serves as a director on the boards of Orthovita, Inc. and Bledsoe, and as an observer for the board of ZIOPHARM Oncology, Inc. He holds a Bachelor of Arts degree from Wesleyan University and a MBA from the Stern School of Business at NYU.

Mr. Tidmore formerly was president and chairman of DePuy Acromed, and formerly was president of DePuy, acquired by Johnson & Johnson in 1999. Mr. Tidmore held various senior management positions during his tenure of over 14 years with Depuy, including responsibilities for international businesses with direct operational responsibilities in several countries across Europe, Latin America, Japan, and Canada. Prior to that Mr. Tidmore served at Ethicon, Inc., where he held several management responsibilities including Vice President of Sales and Marketing in Canada. Mr. Tidmore holds a Marketing degree from the University of Georgia.

Mr. Pegg joined MVP in 2001 and became a Vice President in 2006. Mr. Pegg has served on the boards of several MVP portfolio companies including Composite Technologies, MCMC, and Praxis. Prior to joining MVP, Mr. Pegg was an Analyst for J.P. Morgan Chase Private Bank in Philadelphia. While at J.P. Morgan Chase, Mr. Pegg designed and implemented regional marketing initiatives for brokering private equity offerings. He also developed asset allocation models to craft portfolios tailored to each client's risk and return profile, including models to analyze the suitability of various financial products such as derivatives, credit and estate planning. Mr. Pegg holds a B.A. degree from Yale University, where he was a member of the varsity football team.